Loading…
Genmab reported updated follow-up analyses from a Phase 2 study of petosemtamab in metastatic colorectal cancer. The results showed meaningful objective response rates in patients.
This is a pharmaceutical clinical result with no link to feed, grain, or livestock supply, demand, or prices.
After 224 past report events, ULSD / Diesel moved a median -0.3% over 5 sessions (45% higher; middle half -3.9% to +2.5%), and +0.3% over 20.
Moves of each commodity's benchmark from the last close before the event. Historical reads pool past events of the same kind; they describe what happened, not what will. Not investment advice.